euHeart

Cardiovascular disease (CVD) has a significant impact on the European society in terms of mortality, morbidity and allied healthcare costs. The opportunity of multi-scale modelling spanning, sub-cellular level up to whole heart is to improve CVD outcomes by providing a consistent, biophysically-based framework for the integration of the huge amount of fragmented and inhomogeneous data currently available. However, multi-scale models have not yet been translated into clinical environments mainly due to the difficulty of personalising biophysical models. The challenge of the euHeart project is to directly address this need by combining novel ICT technologies with integrative multi-scale computational models of the heart in clinical environments to improve diagnosis, treatment planning and interventions for CVD.

To meet this challenge we will bring together leading European physiological modelling and cardiac groups to develop, integrate and clinically validate patient-specific computational models of the cardiac physiology and disease-related processes. The main outcome of euHeart will be an open source framework for the description and representation of normal and pathological multi-scale and multi-physics cardiovascular models, using the international encoding standards. In addition, a library of innovative tools for the execution of the biophysical simulations, the personalisation of the models and the automated analysis of multi-modal images are developed.

Evidence of clinical benefit will be collected to quantify potential impact for a number of significant CVD's namely, heart failure, cardiac rhythm disorder, coronary artery disease and valvular and aortic diseases. Each of the selected clinical applications provides a complementary focus for the resulting integrated model of cardiac fluid-electro-mechanical function. The consortium contains a mix of academic leadership, clinical sites, and industrial partners ensuring exploitation of the wealth of models.

For further information, please visit:
http://www.euheart.org

Project co-ordinator:
Philips Technologie GmbH

Partners:

  • INRIA, Institut National de Recherche en Informatique et en Automatique
  • King's College London
  • Academisch Medisch Centrum bij de Universiteit van Amsterdam
  • Polydimensions GmbH
  • Universitat Pompeu Fabra
  • The University of Sheffield
  • Hospital Clinico San Carlos de Madrid Insalud
  • Philips Iberica S.A.
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Volcano Europe SA/NV
  • The Chancellor, Master and Scholars of the University of Oxford
  • HemoLab B.V.
  • Deutsche Krebsforschungszentrum (DKFZ)
  • Berlin Heart GmbH
  • Universität Karlsruhe (Technische Hochschule)
  • Philips Medical Systems Nederland BV

Timetable: from 06/2008 – to 05/2012

Total cost: € 19.053.465

EC funding: € 13.900.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call HORIZON-HLTH-2021-TOOL-06-03: …

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 "Unlocking the full potential of new tools, technologies and digital...

CSAM Acquires Optima - Further Boosts eH…

CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, today announced it has signed a deal to acquire eHealth player Optima Corporation Ltd from...

Novartis and Hewlett Packard Enterprise …

Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to...

COVID-19 Origins Still a Mystery

Scientists using computer modelling to study SARS-CoV-2, the virus that caused the COVID-19 pandemic, have discovered the virus is most ideally adapted to infect human cells - rather than bat...

Using Artificial Intelligence to Overcom…

Depression is a worldwide problem, with serious consequences for individual health and the economy, and rapid and effective screening tools are thus urgently needed to counteract its increasing prevalence. Now...

Deep Machine Learning Completes Informat…

The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has...

EU Digital COVID Certificate Enters into…

The EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across...

Philips and the Spanish National Center …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could...

Scottish Health and Care Professionals G…

Scottish health and care professionals across a wide range of clinical settings including NHS Scotland health boards are being given access to an individual's COVID-19 vaccine status through the Orion...

Ethics and Governance of Artificial Inte…

Artificial Intelligence (AI) refers to the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having...

It's Going to be Quite a Handover…

Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it...

Philips Accelerates Stroke Diagnosis and…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company. Together with the recently expanded stroke...